We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Expands Immunology Pipeline With $11 Billion Prometheus Purchase
Merck Expands Immunology Pipeline With $11 Billion Prometheus Purchase
Merck announced Monday it will acquire Prometheus Biosciences in a nearly $11 billion deal expected to greatly expand the drugmaker’s portfolio of treatments for autoimmune diseases.